<DOC>
	<DOCNO>NCT02627807</DOCNO>
	<brief_summary>The purpose study compare individualize clinical target volume ( CTV ) base disease extension risk atlas computer-aided delineation traditional CTV intensity modulate radiotherapy ( IMRT ) nasopharyngeal carcinoma ( NPC ) , order confirm efficacy safety .</brief_summary>
	<brief_title>Clinical Target Volume Based Disease Extension Risk Atlas Computer-aided Delineation Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Patients non-keratinizing NPC T1-4N0-3M0 ( AJCC/UICC stag system 7th edition ) randomly assign receive IMRT use individualized clinical target volume ( CTV ) base disease extension risk atlas computer-aided delineation IMRT use traditional CTV . IMRT give 2.13 Gray ( Gy ) per fraction five daily fraction per week 6-7 week total dose 70.29 Gy primary tumor . Patients T1N0M0 NPC receive IMRT . For patient stage T2-4N0-3M0 NPC , concurrent chemoradiotherapy ( CCRT ) require induction chemotherapy ( IC ) CCRT optional.Patients participate another randomize trial ( NCT01872962 ) time receive protocol chemotherapy . Induction chemotherapy regimens follow : gemcitabine ( 1000 mg/m² d1,8 ) plus cisplatin ( 80mg/m² d1 ) docetaxel ( 75mg/m² d1 ) plus cisplatin ( 75mg/m² , total dose average d1-d3 ) every 3 week three cycle . concurrent chemotherapy include cisplatin ( 100mg/m² d1 80mg/m² , total dose average d1-d3 ) every 3 week three cycle . Our primary endpoint loco-regional recurrence-free survival ( LRRFS ) rate . Secondary end point include overall survival ( OS ) rate , distant metastasis-free survival ( DMFS ) rate , constituent ratio local regional recurrence pattern , toxic effect , quality life score dosimetric parameter IMRT planning . All efficacy analysis conduct intention-to-treat population , safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients newly histologically confirm nonkeratinizing ( accord WHO histologically type ) . Tumor stag T14N03M0 ( accord 7th AJCC edition ) , base upon follow minimum diagnostic workup within 4 week prior registration : ( 1 ) history/physical examination ; ( 2 ) chest Xray , PA lateral OR chest CT OR PET/CT ; ( 3 ) pretreatment magnetic resonance imaging ( MRI ) nasopharynx neck , pretreatment MRI must do Sun Yatsen University Cancer Center ; ( 4 ) sonography OR CT upper abdoman OR PET/CT ; ( 5 ) Bone scan OR PET/CT . Satisfactory performance status : Karnofsky scale ( KPS ) ≥ 70 . Adequate bone marrow function base upon complete blood count within 2 week prior registration : leucocyte count ≥ 4000/μL , hemoglobin ≥ 90g/L platelet count ≥ 100000/μL . Adequate hepatic function within 2 week prior registration : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) &lt; 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤ 2.5×ULN , bilirubin ≤ ULN . Adequate renal function within 2 week prior registration : serum creatinine ≤ 133 umol/L calculate creatinine clearance ≥ 60 ml/min . Women childbearing potential male participant must agree use medically effective mean birth control throughout participation treatment phase study . Patients must inform investigational nature study sign write informed consent . Age &gt; 65 &lt; 18 . Prior malignancy except adequately treat basal cell squamous cell skin cancer outside head neck region , situ cervical cancer . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . History previous RT ( except nonmelanomatous skin cancer outside intend RT treatment volume ) . Prior chemotherapy surgery ( except fine needle aspiration biopsy ) primary tumor node . Hearing loss due sensorineural deafness（except tumor induce conductive hearing loss ) . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance , untreated active infectious disease , acquire immune deficiency syndrome . Prior allergic reaction study drug involve protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>Intensity modulate radiotherapy</keyword>
	<keyword>Clinical target volume</keyword>
	<keyword>Clinical trial</keyword>
</DOC>